For Noah Weiland's latest contributions to The Japan Times, see below:
The rollout of the COVID-19 treatment Paxlovid has been far more complicated and less efficient than expected, leaving hundreds of thousands of courses unused.
The administration has gotten much right, but its response has been hampered by confusing messaging, a lack of focus on testing, fear of political blowback and the virus’ unpredictability.
The concerns about the shot mirror those about AstraZeneca’s, which European regulators began investigating last month after some recipients developed blood clots.
As the United States enters what may be the most intense stage of the pandemic yet, the Trump administration remains largely disengaged.
